Illumina Inc. (NASDAQ:ILMN) had its target price decreased by Canaccord Genuity from $165.00 to $135.00 in a research report sent to investors on Tuesday. Canaccord Genuity currently has a hold rating on the life sciences company’s stock.
A number of other equities analysts also recently commented on ILMN. Zacks Investment Research upgraded shares of Illumina from a sell rating to a hold rating in a research report on Monday, July 4th. Cantor Fitzgerald restated a hold rating on shares of Illumina in a research report on Wednesday, June 29th. Mizuho upped their price objective on shares of Illumina from $138.00 to $148.00 and gave the stock a neutral rating in a research report on Wednesday, July 27th. Vetr downgraded shares of Illumina from a buy rating to a sell rating and set a $142.96 price objective for the company. in a research report on Tuesday, July 26th. Finally, Janney Montgomery Scott downgraded shares of Illumina from a neutral rating to a sell rating and cut their price objective for the stock from $155.00 to $125.00 in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $159.24.
Shares of Illumina (NASDAQ:ILMN) traded down 0.9609% on Tuesday, hitting $137.6545. 1,110,512 shares of the company traded hands. The company has a market capitalization of $20.18 billion, a PE ratio of 47.1419 and a beta of 0.47. The stock’s 50-day moving average price is $174.01 and its 200-day moving average price is $156.43. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.13. The company earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.80 EPS. On average, equities analysts predict that Illumina will post $3.53 earnings per share for the current year.
In other news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total transaction of $3,459,800.00. Following the sale, the director now owns 508,061 shares in the company, valued at $87,889,472.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roy A. Whitfield sold 4,000 shares of Illumina stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $167.22, for a total transaction of $668,880.00. Following the sale, the director now owns 6,853 shares in the company, valued at approximately $1,145,958.66. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Several hedge funds have recently bought and sold shares of ILMN. Glenmede Trust Co. NA raised its stake in Illumina by 26.2% in the first quarter. Glenmede Trust Co. NA now owns 3,660 shares of the life sciences company’s stock worth $593,000 after buying an additional 760 shares in the last quarter. Virginia Retirement System bought a new stake in shares of Illumina during the first quarter worth about $385,000. IFP Advisors Inc raised its stake in shares of Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock worth $184,000 after buying an additional 774 shares during the period. NN Investment Partners Holdings N.V. bought a new stake in shares of Illumina during the first quarter worth about $403,000. Finally, Menta Capital LLC bought a new stake in shares of Illumina during the first quarter worth about $603,000. Institutional investors own 95.22% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.